ES2284646T3 - Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos. - Google Patents

Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos. Download PDF

Info

Publication number
ES2284646T3
ES2284646T3 ES01932584T ES01932584T ES2284646T3 ES 2284646 T3 ES2284646 T3 ES 2284646T3 ES 01932584 T ES01932584 T ES 01932584T ES 01932584 T ES01932584 T ES 01932584T ES 2284646 T3 ES2284646 T3 ES 2284646T3
Authority
ES
Spain
Prior art keywords
fenofibrate
statin
drug
phospholipid
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01932584T
Other languages
English (en)
Spanish (es)
Inventor
Pol-Henri Guivarc'h
Indu Parikh
Robert A. Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Application granted granted Critical
Publication of ES2284646T3 publication Critical patent/ES2284646T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Meat, Egg Or Seafood Products (AREA)
ES01932584T 2001-02-22 2001-04-20 Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos. Expired - Lifetime ES2284646T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27015701P 2001-02-22 2001-02-22
US270157P 2001-02-22

Publications (1)

Publication Number Publication Date
ES2284646T3 true ES2284646T3 (es) 2007-11-16

Family

ID=23030144

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01932584T Expired - Lifetime ES2284646T3 (es) 2001-02-22 2001-04-20 Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos.

Country Status (13)

Country Link
US (3) US6534088B2 (enExample)
EP (1) EP1361867B1 (enExample)
JP (1) JP2004523552A (enExample)
CN (1) CN1273112C (enExample)
AT (1) ATE357216T1 (enExample)
AU (1) AU2001259099B2 (enExample)
CA (1) CA2440355C (enExample)
DE (1) DE60127457T2 (enExample)
ES (1) ES2284646T3 (enExample)
NZ (1) NZ527408A (enExample)
PL (1) PL202778B1 (enExample)
TW (1) TWI288000B (enExample)
WO (1) WO2002067901A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
BR9915738A (pt) * 1998-11-20 2001-10-02 Rtp Pharma Inc Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
MXPA01008955A (es) 1999-03-05 2002-04-24 Procter & Gamble Analogos de prostaglandinas selectivas de fp no saturadas de c16.
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2003013607A1 (en) * 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
WO2003055467A1 (en) * 2001-12-18 2003-07-10 Synthon B.V. Simvastatin dosage forms
WO2003066021A2 (en) 2002-02-04 2003-08-14 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
WO2003079026A1 (en) * 2002-03-12 2003-09-25 Phillips Paul S Method of diagnosing statin myopathy
JP4831965B2 (ja) * 2002-06-10 2011-12-07 エラン ファーマ インターナショナル，リミティド ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
JP2005531606A (ja) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
CN1812983A (zh) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
DE60331963D1 (de) * 2003-08-06 2010-05-12 Galephar M F Stabile pharmazeutische zubereitungen zur kontrollierten freisetzung von fenofibrat and pravastatin
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
MXPA06003813A (es) * 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
DE602004030931D1 (enExample) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
EP1680100A4 (en) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc QUATERNARY AMMONIUM COMPOUNDS CONTAINING BIOAVAILABILITY ACTIVATORS
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
JPWO2006011495A1 (ja) * 2004-07-30 2008-05-01 興和株式会社 高コレステロール血症及び／又は高トリグリセリド血症治療剤
WO2006017698A2 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
AU2005271407A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
WO2006037346A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and simvastatin
EP1853249A2 (en) * 2005-02-10 2007-11-14 LifeCycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
CA2603105A1 (en) * 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
WO2006084475A2 (en) * 2005-04-13 2006-08-17 Lifecycle Pharma A/S A tablet comprising a fibrate
BRPI0616695A2 (pt) * 2005-09-28 2011-06-28 Dnp Canada Inc combinação de poliquitosamina e fibrato para a prevenção e o tratamento de hiperlipidemia
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
EP1785133A1 (en) 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
CN101534825A (zh) 2006-08-04 2009-09-16 Aska制药株式会社 含有贝特类药物的制剂及其制备方法
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
MXPA06010973A (es) * 2006-09-25 2009-02-18 World Trade Imp Export Wtie Ag Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia.
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
WO2008057048A1 (en) * 2006-11-09 2008-05-15 Nanomaterials Technology Pte Ltd Nano & micro-sized particles of statin compounds and process for forming same
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
AU2008281640A1 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
CA2746887C (en) 2008-12-15 2016-07-05 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
JP2012096998A (ja) * 2009-02-27 2012-05-24 Kowa Co 安定なカプセル製剤及びその製造方法
WO2011028757A1 (en) * 2009-09-01 2011-03-10 First Tech International Limited Tocotrienol compositions
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
KR102055542B1 (ko) 2015-03-10 2019-12-13 시오노기 잉크 고체 분산체
CA3016764A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
MA44764B1 (fr) * 2016-04-28 2025-09-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de patients présentant une hypercholestérolémie familiale
MX2022015336A (es) * 2020-09-29 2023-01-11 Laboratorios Silanes S A De C V Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803582A (en) * 1956-07-16 1957-08-20 Leonid S Cherney Local anesthetic composition
NL120093C (enExample) * 1958-07-24
US3137631A (en) * 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3216897A (en) * 1961-11-02 1965-11-09 Air Reduction Injectable anesthetic
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
NL7012832A (enExample) * 1970-08-29 1972-03-02
US3715432A (en) * 1971-01-22 1973-02-06 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3794476A (en) * 1972-12-26 1974-02-26 Ppg Industries Inc Method for thermally tempering glass sheet by liquid quenching
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
US3965255A (en) * 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
CH588887A5 (enExample) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
JPS5231981A (en) * 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
US4320121A (en) * 1976-10-12 1982-03-16 Sears Barry D Method of emulsifying cholesterol, cholesterol esters and triglyceride compounds
US4351831A (en) * 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) * 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
DE2965725D1 (en) * 1978-07-19 1983-07-28 Patrick Couvreur Biodegradable nanoparticles, pharmaceutical compositions containing them and process for their preparation
US4219548A (en) * 1978-09-01 1980-08-26 The Procter & Gamble Company Topical anti-inflammatory composition
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
US4369182A (en) * 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
GR73668B (enExample) * 1978-11-21 1984-03-28 Hoffmann La Roche
US4328222A (en) * 1978-11-21 1982-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions for parenteral or local administration
US4378354A (en) * 1978-12-27 1983-03-29 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
DE2914788A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
JPS6030652B2 (ja) * 1979-05-07 1985-07-17 株式会社ミドリ十字 静脈注射用脂肪乳剤
JPS562353A (en) * 1979-06-20 1981-01-12 Ricoh Co Ltd Novel disazo compound and its preparation
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
DE3003886A1 (de) * 1980-02-02 1981-08-13 Olympia Werke Ag, 2940 Wilhelmshaven Farbbandkassette fuer eine schreib- o.ae. bueromaschine
AR220263A1 (es) * 1980-02-19 1980-10-15 Bago Lab Sa Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad
JPS609726B2 (ja) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4397846A (en) * 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
JPS601122A (ja) * 1983-06-20 1985-01-07 Green Cross Corp:The ビフエニリルプロピオン酸誘導体脂肪乳剤
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4532089A (en) * 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
JPS61174940A (ja) * 1985-01-29 1986-08-06 Oogawara Kakoki Kk ワックス類コーテイング単核状マイクロカプセルおよびその製造方法
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
US4766046A (en) * 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
JPH0617309B2 (ja) * 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DE3623376A1 (de) * 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
BR9915738A (pt) * 1998-11-20 2001-10-02 Rtp Pharma Inc Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001080828A2 (en) * 2000-04-20 2001-11-01 Rtp Pharma Inc. Improved water-insoluble drug particle process
AU5967101A (en) * 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect

Also Published As

Publication number Publication date
PL364174A1 (en) 2004-12-13
US6534088B2 (en) 2003-03-18
CN1273112C (zh) 2006-09-06
DE60127457T2 (de) 2007-11-29
HK1061357A1 (en) 2004-09-17
DE60127457D1 (de) 2007-05-03
ATE357216T1 (de) 2007-04-15
JP2004523552A (ja) 2004-08-05
AU2001259099B2 (en) 2005-12-22
US20040086571A1 (en) 2004-05-06
CN1505502A (zh) 2004-06-16
CA2440355C (en) 2011-03-08
EP1361867A1 (en) 2003-11-19
CA2440355A1 (en) 2002-09-06
PL202778B1 (pl) 2009-07-31
EP1361867B1 (en) 2007-03-21
US20120064160A1 (en) 2012-03-15
TWI288000B (en) 2007-10-11
WO2002067901A1 (en) 2002-09-06
US20020161032A1 (en) 2002-10-31
NZ527408A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
ES2284646T3 (es) Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos.
US6696084B2 (en) Spray drying process and compositions of fenofibrate
AU2001259099A1 (en) Fibrate-statin combinations with reduced fed-fasted effects
AU2007201953B2 (en) Stabilised fibrate microparticles
JP5102423B2 (ja) 改善された水不溶性薬剤粒子の処理
ES2946493T3 (es) Formulaciones de fibrato en nanopartículas
AU2001262945A1 (en) Spray drying process and compositions of fenofibrate
US8586094B2 (en) Coated tablets
CA2484375C (en) Oral dosage forms comprising fenofibrate
HK1061357B (en) Fibrate-statin combinations with reduced fed-fasted effects
HK1143747A (en) Oral dosage forms comprising fenofibrate